Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neuronetics, Inc. (STIM)

Neuronetics Q2 revenue rises 9.1% to $41.6 million; net loss narrows to $3.4 million

Mixed Impact 4 of 5 earnings Written later

Neuronetics reported second-quarter 2026 revenue of $41.6 million, up 9.1% from a year earlier, driven by Greenbrook clinic revenue. Net loss narrowed to $3.4 million from $10.1 million, but the company trimmed the top end of its full-year 2026 revenue guidance and appointed a new chief financial officer.

Key points

  • Total revenue $41.6 million, up 9.1%; Greenbrook revenue $26.9 million, up 16.8%
  • Net loss $3.4 million, or $0.05 per share, versus $10.1 million, or $0.15 per share, a year earlier
  • FY2026 revenue guidance $160 million to $164 million, versus prior $160 million to $166 million
  • Nir Naor appointed Executive Vice President and Chief Financial Officer

The filing

CompanyNeuronetics, Inc. (STIM)
Form8-K, current report
Filed with the SECAug 11, 2026, 8:05 AM ET
Accession number0001193125-26-343474

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.